Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Dravet Syndrome
- Main trialPhase 1/2
- “The primary purpose of this study is to evaluate the safety and tolerability of ION337 in participants with Dravet syndrome (DS).”In the company’s words, NCT07531745 on ClinicalTrials.gov
Other drugs for Dravet Syndrome
- LP352Longboard Pharmaceuticals · Phase 3
- ZorevunersenStoke Therapeutics, Inc · Phase 3
- Clemizole HClEpygenix · Phase 3
- ETX101Encoded Therapeutics · Phase 1/2
- BMB-101Bright Minds Biosciences · Phase 2
- CannabidiolJazz Pharmaceuticals · Marketed (Phase 4 trial)
Coming up1
- Dec 2030Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Dec 2030 | ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026